SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q/A - Quarterly report [Sections 13 or 15(d)]: [Amend]
SEC Accession No. 0001628280-18-011245
Filing Date
2018-08-20
Accepted
2018-08-20 16:24:45
Documents
4
Period of Report
2018-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q mrtx-20180331x10q.htm 10-Q/A 61029
2 EXHIBIT 10.1 mrtxex101new.htm EX-10.1 477250
3 EXHIBIT 31.3 mrtx033118ex313.htm EX-31.3 5001
4 EXHIBIT 31.4 mrtx033118ex314.htm EX-31.4 5959
  Complete submission text file 0001628280-18-011245.txt   550274
Mailing Address 9393 TOWNE CENTRE DRIVE SUITE 200 SAN DIEGO CA 92121
Business Address 9393 TOWNE CENTRE DRIVE SUITE 200 SAN DIEGO CA 92121 858-332-3410
Mirati Therapeutics, Inc. (Filer) CIK: 0001576263 (see all company filings)

IRS No.: 462693615 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q/A | Act: 34 | File No.: 001-35921 | Film No.: 181028486
SIC: 2834 Pharmaceutical Preparations
Assistant Director 1